David RP Almeida

About David RP Almeida

“My motivation over the last 18 months has been driven by a singular realization: the traditional silos of clinical research, surgical training, and molecular discovery are failing to keep pace with patient needs. We are treating 21st-century diseases with 20th-century workflows. My work has focused on dismantling these silos and creating an integrated ecosystem that accelerates discovery while de-risking development.

“Specifically, my motivation stems from two critical gaps I identified in the field:

“1. For decades, we treated the eye based on surface-level phenotypes because tissue biopsies were too dangerous. Now, the living eye is no longer a black box; we changed this paradigm with ClinOmicsAI and our TEMPO technology. By integrating liquid-biopsy proteomics with single-cell transcriptomics and AI, we can now trace the cellular origin of nearly 6,000 proteins in aqueous humor. In the last year, this approach allowed us to identify that retinal degeneration occurs in Parkinson’s disease and that the cellular drivers of diabetic retinopathy shift as the disease progresses.

“2. There is a clinical trial efficiency crisis. The industry standard for trial recruitment is broken, slow, expensive, and geographically limited. My response was to engineer the CASEx Global Network. By deploying AI-driven tools (via CASExAI) such as SurgMAPai (surgical mapping), SKYE (Study Coordinator AI), and bloc enrollment strategies (BES), we can accelerate clinical trial execution without compromising safety or the robustness of the data. We have shown that an independent site could outperform major institutions, achieving a 94% trial completion rate and 100% FDA audit success rate over six years.

“The impact of this work is the creation of a vertical integration model for complex ophthalmology and vitreoretinal clinical trials. We are no longer just running trials; we are identifying molecular targets via liquid biopsy (ClinOmicsAI), testing them in our optimized global sites and ensuring regulatory integrity via AI oversight. This approach has saved sponsors millions per drug development cycle and reduced trial timelines by up to 40%.

“My goal is to ensure that drivers of change are not just concepts, but operational realities that bring therapies to patients faster, safer, and with greater precision.”